This HTML5 document contains 200 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/pubchem-compound/
n8http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/iuphar/
n9http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/guide-to-pharmacology/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/national-drug-code-directory/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/chemspider/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n27http://www.rxlist.com/cgi/generic2/
n13http://linked.opendata.cz/resource/drugbank/property/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/wikipedia/
n26http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00798/identifier/kegg-compound/
n12http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00798
rdf:type
n3:Drug
n3:description
A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1a, obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation). [PubChem]
n3:dosage
n29:271B6554-363D-11E5-9242-09173F13E4C5 n29:271B6555-363D-11E5-9242-09173F13E4C5 n29:271B655A-363D-11E5-9242-09173F13E4C5 n29:271B655B-363D-11E5-9242-09173F13E4C5 n29:271B655C-363D-11E5-9242-09173F13E4C5 n29:271B655D-363D-11E5-9242-09173F13E4C5 n29:271B6556-363D-11E5-9242-09173F13E4C5 n29:271B6557-363D-11E5-9242-09173F13E4C5 n29:271B6558-363D-11E5-9242-09173F13E4C5 n29:271B6559-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
3-3½ hours in infants one week to six months of age; this increases to 5½ hours in full-term and large premature infants less than one week old.
n3:indication
For treatment of serious infections caused by susceptible strains of the following microorganisms: <i>P. aeruginosa</i>, <i>Proteus</i> species (indole-positive and indole-negative), <i>E. coli</i>, <i>Klebsiella-Enterobactor-Serratia</i> species, <i>Citrobacter</i> species and <i>Staphylococcus</i> species (coagulase-positive and coagulase-negative).
n3:manufacturer
n4:271B6523-363D-11E5-9242-09173F13E4C5 n4:271B6528-363D-11E5-9242-09173F13E4C5 n4:271B6529-363D-11E5-9242-09173F13E4C5 n4:271B6526-363D-11E5-9242-09173F13E4C5 n4:271B6527-363D-11E5-9242-09173F13E4C5 n4:271B652C-363D-11E5-9242-09173F13E4C5 n4:271B652D-363D-11E5-9242-09173F13E4C5 n4:271B652A-363D-11E5-9242-09173F13E4C5 n4:271B652B-363D-11E5-9242-09173F13E4C5 n4:271B6530-363D-11E5-9242-09173F13E4C5 n4:271B6531-363D-11E5-9242-09173F13E4C5 n4:271B652E-363D-11E5-9242-09173F13E4C5 n4:271B652F-363D-11E5-9242-09173F13E4C5 n4:271B6534-363D-11E5-9242-09173F13E4C5 n4:271B6535-363D-11E5-9242-09173F13E4C5 n4:271B6532-363D-11E5-9242-09173F13E4C5 n4:271B6533-363D-11E5-9242-09173F13E4C5 n4:271B6538-363D-11E5-9242-09173F13E4C5 n4:271B6539-363D-11E5-9242-09173F13E4C5 n4:271B6536-363D-11E5-9242-09173F13E4C5 n4:271B6537-363D-11E5-9242-09173F13E4C5 n4:271B653A-363D-11E5-9242-09173F13E4C5 n4:271B651C-363D-11E5-9242-09173F13E4C5 n4:271B651D-363D-11E5-9242-09173F13E4C5 n4:271B6520-363D-11E5-9242-09173F13E4C5 n4:271B6521-363D-11E5-9242-09173F13E4C5 n4:271B651E-363D-11E5-9242-09173F13E4C5 n4:271B651F-363D-11E5-9242-09173F13E4C5 n4:271B6524-363D-11E5-9242-09173F13E4C5 n4:271B6525-363D-11E5-9242-09173F13E4C5 n4:271B6522-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00798 n25:DB00798
dcterms:title
Gentamicin
adms:identifier
n15:3348 n16:DB00798 n17:17833 n18:2427 n19:C00505 n20:2427 n21:3467 n22:46506523 n23:17478-283-10 n24:PA449753 n30:Gentamicin
n3:mechanismOfAction
Aminoglycosides like gentamicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically gentamicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.
n3:packager
n4:271B651A-363D-11E5-9242-09173F13E4C5 n4:271B651B-363D-11E5-9242-09173F13E4C5 n4:271B6518-363D-11E5-9242-09173F13E4C5 n4:271B6519-363D-11E5-9242-09173F13E4C5 n4:271B6516-363D-11E5-9242-09173F13E4C5 n4:271B6517-363D-11E5-9242-09173F13E4C5 n4:271B6514-363D-11E5-9242-09173F13E4C5 n4:271B6515-363D-11E5-9242-09173F13E4C5 n4:271B6512-363D-11E5-9242-09173F13E4C5 n4:271B6513-363D-11E5-9242-09173F13E4C5 n4:271B64F0-363D-11E5-9242-09173F13E4C5 n4:271B64F1-363D-11E5-9242-09173F13E4C5 n4:271B64EE-363D-11E5-9242-09173F13E4C5 n4:271B64EF-363D-11E5-9242-09173F13E4C5 n4:271B6510-363D-11E5-9242-09173F13E4C5 n4:271B6511-363D-11E5-9242-09173F13E4C5 n4:271B650E-363D-11E5-9242-09173F13E4C5 n4:271B650F-363D-11E5-9242-09173F13E4C5 n4:271B650C-363D-11E5-9242-09173F13E4C5 n4:271B650D-363D-11E5-9242-09173F13E4C5 n4:271B650A-363D-11E5-9242-09173F13E4C5 n4:271B650B-363D-11E5-9242-09173F13E4C5 n4:271B6508-363D-11E5-9242-09173F13E4C5 n4:271B6509-363D-11E5-9242-09173F13E4C5 n4:271B6506-363D-11E5-9242-09173F13E4C5 n4:271B6507-363D-11E5-9242-09173F13E4C5 n4:271B6504-363D-11E5-9242-09173F13E4C5 n4:271B6505-363D-11E5-9242-09173F13E4C5 n4:271B6502-363D-11E5-9242-09173F13E4C5 n4:271B6503-363D-11E5-9242-09173F13E4C5 n4:271B6500-363D-11E5-9242-09173F13E4C5 n4:271B6501-363D-11E5-9242-09173F13E4C5 n4:271B64FE-363D-11E5-9242-09173F13E4C5 n4:271B64FF-363D-11E5-9242-09173F13E4C5 n4:271B64FC-363D-11E5-9242-09173F13E4C5 n4:271B64FD-363D-11E5-9242-09173F13E4C5 n4:271B64FA-363D-11E5-9242-09173F13E4C5 n4:271B64FB-363D-11E5-9242-09173F13E4C5 n4:271B64F8-363D-11E5-9242-09173F13E4C5 n4:271B64F9-363D-11E5-9242-09173F13E4C5 n4:271B64F6-363D-11E5-9242-09173F13E4C5 n4:271B64F7-363D-11E5-9242-09173F13E4C5 n4:271B64F4-363D-11E5-9242-09173F13E4C5 n4:271B64F5-363D-11E5-9242-09173F13E4C5 n4:271B64F2-363D-11E5-9242-09173F13E4C5 n4:271B64F3-363D-11E5-9242-09173F13E4C5
n3:synonym
Gentamicin
n3:toxicity
Mild and reversible nephrotoxicity may be observed in 5 - 25% of patients. Gentamicin accumulates in proximal renal tubular cells and causes cell damage. Tubular cell regeneration occurs despite continued drug exposure. Toxicity usually occurs several days following initiation of therapy. May cause irreversible ototoxicity. Otoxocity appears to be correlated to cumulative lifetime exposure. Drug accumulation in the endolymph and perilymph of the inner ear causes irreversible damage to hair cells of the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing is lost first with progression leading to loss of low frequency hearing. Further toxicity may lead to retrograde degeneration of the 8th cranial (vestibulocochlear) nerve. Vestibular toxicity may cause vertigo, nausea, vomiting, dizziness and loss of balance. Mouse, intravenous LD50: 52 mg/kg; rat, intravenous LD50: 96 mg/kg.
n7:hasAHFSCode
n8:84-04-04 n8:52-04-04 n8:08-12-02
n3:mixture
n9:271B64EB-363D-11E5-9242-09173F13E4C5 n9:271B64E0-363D-11E5-9242-09173F13E4C5 n9:271B64E1-363D-11E5-9242-09173F13E4C5 n9:271B64E4-363D-11E5-9242-09173F13E4C5 n9:271B64E5-363D-11E5-9242-09173F13E4C5 n9:271B64E2-363D-11E5-9242-09173F13E4C5 n9:271B64E3-363D-11E5-9242-09173F13E4C5 n9:271B64E8-363D-11E5-9242-09173F13E4C5 n9:271B64E9-363D-11E5-9242-09173F13E4C5 n9:271B64E6-363D-11E5-9242-09173F13E4C5 n9:271B64E7-363D-11E5-9242-09173F13E4C5 n9:271B64ED-363D-11E5-9242-09173F13E4C5 n9:271B64EA-363D-11E5-9242-09173F13E4C5 n9:271B64EC-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Low (between 0 and 30%)
n3:salt
n3:synthesisReference
George H. Scherr, "Preparation of gentamicin sensitized particles for agglutination tests." U.S. Patent US4100268, issued August, 1975.
foaf:page
n6:gentamicin-drops.html n26:gar1187.shtml n27:pedgenta.htm
n3:IUPAC-Name
n13:271B6562-363D-11E5-9242-09173F13E4C5
n3:InChI
n13:271B6568-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n13:271B6567-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n13:271B6564-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n13:271B6565-363D-11E5-9242-09173F13E4C5
n3:SMILES
n13:271B6566-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n13:271B6578-363D-11E5-9242-09173F13E4C5 n13:271B6560-363D-11E5-9242-09173F13E4C5
n3:logP
n13:271B657A-363D-11E5-9242-09173F13E4C5 n13:271B6561-363D-11E5-9242-09173F13E4C5 n13:271B655E-363D-11E5-9242-09173F13E4C5
n3:logS
n13:271B655F-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n12:S01AA11 n12:S02AA14 n12:S03AA06 n12:D06AX07 n12:J01GB03
n3:H-Bond-Acceptor-Count
n13:271B656E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n13:271B656F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n13:271B6569-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n13:271B656A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n13:271B656C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n13:271B656B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n13:271B656D-363D-11E5-9242-09173F13E4C5
n3:absorption
Injections lead to peak serum concentrations in 30-60 minutes. Topical gentamicin is readily absorbed from large burned, denuded, or granulating areas but not through intact skin. Absorption of gentamicin is faster and greater with the cream compared to the ointment. Gentamicin is absorbed in small quantities following topical application to the eye. Gentamicin is also absorbed in small amounts following topical application to the ear (especially if the eardrum is perforated or if tissue damage is present). Gentamicin is very poorly absorbed orally.
n3:affectedOrganism
Francisella tularensis Yersinia pestis Proteus vulgaris Pseudomonas aeruginosa Enteric bacteria and other eubacteria Serratia marcescens
n3:casRegistryNumber
1403-66-3
n3:category
n3:containedIn
n28:271B6553-363D-11E5-9242-09173F13E4C5 n28:271B6551-363D-11E5-9242-09173F13E4C5 n28:271B653F-363D-11E5-9242-09173F13E4C5 n28:271B6552-363D-11E5-9242-09173F13E4C5 n28:271B654F-363D-11E5-9242-09173F13E4C5 n28:271B6540-363D-11E5-9242-09173F13E4C5 n28:271B653D-363D-11E5-9242-09173F13E4C5 n28:271B6550-363D-11E5-9242-09173F13E4C5 n28:271B653E-363D-11E5-9242-09173F13E4C5 n28:271B654D-363D-11E5-9242-09173F13E4C5 n28:271B654E-363D-11E5-9242-09173F13E4C5 n28:271B653B-363D-11E5-9242-09173F13E4C5 n28:271B653C-363D-11E5-9242-09173F13E4C5 n28:271B654B-363D-11E5-9242-09173F13E4C5 n28:271B654C-363D-11E5-9242-09173F13E4C5 n28:271B6549-363D-11E5-9242-09173F13E4C5 n28:271B654A-363D-11E5-9242-09173F13E4C5 n28:271B6547-363D-11E5-9242-09173F13E4C5 n28:271B6548-363D-11E5-9242-09173F13E4C5 n28:271B6545-363D-11E5-9242-09173F13E4C5 n28:271B6546-363D-11E5-9242-09173F13E4C5 n28:271B6543-363D-11E5-9242-09173F13E4C5 n28:271B6544-363D-11E5-9242-09173F13E4C5 n28:271B6541-363D-11E5-9242-09173F13E4C5 n28:271B6542-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n13:271B6574-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n13:271B6576-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n13:271B6577-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n13:271B6579-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n13:271B6573-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n13:271B6572-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n13:271B6575-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n13:271B6563-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n13:271B6570-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n13:271B6571-363D-11E5-9242-09173F13E4C5